Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Observational 2Interventional 2

Sponsor

Cancer Type

Gastrointestinal 53Thoracic 45Dermatologic 15Head & Neck 13Breast 8Gynecologic 7CNS 7Genitourinary 6Tumor-Agnostic 4Sarcoma 4Other solid neoplasm 4Other hematologic neoplasm 4Lymphoid 4Plasma cell 2Myeloid 2Classical hematology 1

Conditions

Multiple Myeloma 2

Interventions

Dexamethasone 871Bortezomib 457Lenalidomide 456Cyclophosphamide 365Melphalan 272Calcium Dobesilate 263daratumumab 234pomalidomide 208carfilzomib 182fludarabine phosphate 140fludarabine 136Thalidomide 125Peripheral Blood Stem Cell Transplantation 119Filgrastim 114ixazomib 93Mycophenolic Acid 90Granulocyte Colony-Stimulating Factor 89Whole-Body Irradiation 87Busulfan 87dexamethasone acetate 86Tacrolimus 78dexamethasone 21-phosphate 74isatuximab 69Cyclosporine 68auricularum 67Prednisone 65elotuzumab 58belantamab mafodotin 57Antilymphocyte Serum 56Etoposide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Immunotherapy × Plasma cell × Clear all
NCT05950113 2024-05-01

CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Jonsson Comprehensive Cancer Center

Phase 1 Withdrawn
Plasma cell

Multiple Myeloma

NCT03634800 2021-08-05

RISE-M

Weill Medical College of Cornell University

Phase 2 Terminated
6 enrolled 11 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡